30 F.4th 160
3rd Cir.2022Background:
- Englewood Healthcare Foundation (a single-community hospital) agreed to merge with Hackensack Meridian Health (New Jersey’s largest health system). The FTC sued under §13(b) seeking a preliminary injunction pending its administrative challenge under §7 of the Clayton Act.
- District Court held a seven-day evidentiary hearing, admitted extensive evidence, and granted the FTC a preliminary injunction, finding the FTC likely to succeed on the merits.
- The District Court adopted the product market as inpatient general acute-care services sold to commercial insurers and defined the geographic market as Bergen County (patient-based: all hospitals serving Bergen County residents).
- FTC’s evidence: post-merger HHI = 2,835 (highly concentrated) with an 841-point increase; diversion ratios; insurer testimony that Bergen County is economically significant; expert Dafny’s willingness-to-pay/bargaining-leverage model estimating substantial post-merger price increases.
- Hospitals defended with claimed procompetitive benefits (capital investments, expanded tertiary/quaternary services, cost savings, quality improvements) and argued errors in market definition and econometrics; District Court found efficiencies largely speculative or non–merger-specific.
- Third Circuit affirmed: no legal error in patient-based market definition, hypothetical monopolist test application, prima facie showing of anticompetitive effects, and rejection of the Hospitals’ efficiencies rebuttal.
Issues:
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| 1. Proper geographic market definition | FTC: Bergen County (patient-based) is the correct market; insurer testimony and SSNIP analysis support it | Hospitals: patient-based market requires proof that price discrimination across patient groups is feasible; FTC failed that proof | Court: No rigid price-discrimination prerequisite; market may be patient-based and was properly defined and supported by evidence |
| 2. Use/application of hypothetical monopolist (SSNIP) test | FTC: Dafny’s willingness-to-pay/bargaining leverage model and insurer evidence satisfy SSNIP for Bergen County | Hospitals: Dafny tested a hospital-based subset and improperly extrapolated; failed to consider cross-county patient flows | Court: Extrapolation and methodology reasonable in healthcare context; no clear error in applying SSNIP to patient-based market |
| 3. Prima facie showing of anticompetitive effects | FTC: HHI indicates high concentration and large increase; diversion ratios, insurer projections, and prior Hackensack post-acquisition pricing support likely price increases | Hospitals: HHI barely exceeds threshold; econometric estimates unreliable; disputed data choices | Court: HHI and direct evidence create a strong prima facie case; expert analyses supported by alternative data undermine defendants’ criticisms |
| 4. Rebuttal by efficiencies / procompetitive benefits | Hospitals: merger will yield substantial upgrades, capacity, cost savings, and quality improvements that offset harms | FTC: claimed benefits are speculative, non–merger-specific, or unverifiable; efficiencies must be merger-specific and verifiable to rebut prima facie case | Court: Hospitals failed to meet efficiencies requirements; claimed benefits inadequate to overcome likely competitive harms |
Key Cases Cited
- Brown Shoe Co. v. United States, 370 U.S. 294 (1962) (§7 focuses on probabilities and commercial realities for market definition)
- FTC v. Penn State Hershey Med. Ctr., 838 F.3d 327 (3d Cir. 2016) (three-part burden shifting in hospital merger cases; discussed efficiencies standard)
- St. Alphonsus Med. Ctr.-Nampa, Inc. v. St. Luke’s Health Sys., Ltd., 778 F.3d 775 (9th Cir. 2015) (patient- and physician-location approaches to geographic market in healthcare)
- United States v. Marine Bancorporation, Inc., 418 U.S. 602 (1974) (market definition is a necessary predicate in merger analysis)
- United States v. Eastman Kodak Co., 63 F.3d 95 (2d Cir. 1995) (customer-based market analysis and price-discrimination theory)
- FTC v. H.J. Heinz Co., 246 F.3d 708 (D.C. Cir. 2001) (use of HHI to assess concentration and merger effects)
- Univ. Health, Inc. v. FTC, 938 F.2d 1206 (11th Cir. 1991) (efficiencies defense framework and burden for proving consumer-benefiting economies)